跌破眼球!默沙东新冠病毒口服药有效率降至30%!

2021-11-26 Armstrong生物药资讯 Armstrong生物药资讯

2021年11月26日,默沙东和Ridgeback宣布新冠口服药Molnupiravir治疗轻度至中度新冠的更新临床数据。根据全部入住患者数据,降低住院率或死亡率30%。安慰剂组有9例死亡,治疗组有1

2021年11月26日,默沙东和Ridgeback宣布新冠口服药Molnupiravir治疗轻度至中度新冠的更新临床数据。根据全部入住患者数据,降低住院率或死亡率30%。安慰剂组有9例死亡,治疗组有1例死亡。

图片

图片

2021年10月1日,默沙东与Ridgeback宣布Molnupiravir治疗轻度至中度新冠肺炎患者的三期临床中期数据,Molnupiravir治疗组的住院或死亡率为7.3%(28/385),对照组的住院或死亡率为14.1%(53/377),Molnupiravir降低住院或死亡率50%,p值为0.0012。死亡率方面,治疗组没有死亡,对照组有8例死亡。(见:默沙东治疗新冠肺炎口服特效药Molnupiravir取得良好效果,降低住院或死亡率50%,未来可能是治疗新冠的决定性药物之一

而且英国在全球第一个批准了Molnupiravir在英国上市,见:英国批准默沙东新冠口服药物molnupiravir,开创新冠治疗的新时代!这是不是大写的尴尬?

图片

Molnupiravir此次更新的全部患者有效率仅30%,远远低于中期分析的50%。受此消息影响,默沙东盘前股价下跌4%,竞争对手辉瑞盘前股价上涨6%,mRNA疫苗公司Moderna股价上涨13%,BioNtech股价上涨10%。

总结

近两个月来,对新冠疫情的情绪在希望与焦虑中反复变化,相关药企的股价也随之跌宕起伏。默沙东与辉瑞新冠口服药的成功,让战胜疫情的信心大涨。然而疫情看来不会轻易退去,默沙东口服药有效率大幅下降,南非新突变株B.1.1.519可能为超级变种,再次引发广泛焦虑。

链接:全球五大口服治疗新冠病毒感染药物研发进展,未来是抗新冠病毒主要力量

图片

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684064, encodeId=3a3c168406440, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Thu Jan 06 17:26:19 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060883, encodeId=98d4206088380, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sun Mar 06 15:26:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076977, encodeId=0f8610e6977c8, content=还需努力哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Sun Dec 05 05:37:53 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259994, encodeId=abf81259994d2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Nov 28 14:26:19 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074384, encodeId=2c1c10e4384c0, content=药物的研发还是需要时间,静静等待就好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/fdb40d331d654a408c5c21ba2cc99d8e/e9157a03ad7a4e8ca944ff70d9565fc7.jpg, createdBy=f6da5502104, createdName=大郎该吃药了, createdTime=Sat Nov 27 06:33:31 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-01-06 刘阔
  2. [GetPortalCommentsPageByObjectIdResponse(id=1684064, encodeId=3a3c168406440, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Thu Jan 06 17:26:19 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060883, encodeId=98d4206088380, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sun Mar 06 15:26:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076977, encodeId=0f8610e6977c8, content=还需努力哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Sun Dec 05 05:37:53 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259994, encodeId=abf81259994d2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Nov 28 14:26:19 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074384, encodeId=2c1c10e4384c0, content=药物的研发还是需要时间,静静等待就好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/fdb40d331d654a408c5c21ba2cc99d8e/e9157a03ad7a4e8ca944ff70d9565fc7.jpg, createdBy=f6da5502104, createdName=大郎该吃药了, createdTime=Sat Nov 27 06:33:31 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-03-06 gdsun
  3. [GetPortalCommentsPageByObjectIdResponse(id=1684064, encodeId=3a3c168406440, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Thu Jan 06 17:26:19 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060883, encodeId=98d4206088380, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sun Mar 06 15:26:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076977, encodeId=0f8610e6977c8, content=还需努力哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Sun Dec 05 05:37:53 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259994, encodeId=abf81259994d2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Nov 28 14:26:19 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074384, encodeId=2c1c10e4384c0, content=药物的研发还是需要时间,静静等待就好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/fdb40d331d654a408c5c21ba2cc99d8e/e9157a03ad7a4e8ca944ff70d9565fc7.jpg, createdBy=f6da5502104, createdName=大郎该吃药了, createdTime=Sat Nov 27 06:33:31 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-12-05 yx1156

    还需努力哦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1684064, encodeId=3a3c168406440, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Thu Jan 06 17:26:19 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060883, encodeId=98d4206088380, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sun Mar 06 15:26:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076977, encodeId=0f8610e6977c8, content=还需努力哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Sun Dec 05 05:37:53 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259994, encodeId=abf81259994d2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Nov 28 14:26:19 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074384, encodeId=2c1c10e4384c0, content=药物的研发还是需要时间,静静等待就好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/fdb40d331d654a408c5c21ba2cc99d8e/e9157a03ad7a4e8ca944ff70d9565fc7.jpg, createdBy=f6da5502104, createdName=大郎该吃药了, createdTime=Sat Nov 27 06:33:31 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-28 yese
  5. [GetPortalCommentsPageByObjectIdResponse(id=1684064, encodeId=3a3c168406440, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Thu Jan 06 17:26:19 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060883, encodeId=98d4206088380, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sun Mar 06 15:26:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076977, encodeId=0f8610e6977c8, content=还需努力哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Sun Dec 05 05:37:53 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259994, encodeId=abf81259994d2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Nov 28 14:26:19 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074384, encodeId=2c1c10e4384c0, content=药物的研发还是需要时间,静静等待就好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/fdb40d331d654a408c5c21ba2cc99d8e/e9157a03ad7a4e8ca944ff70d9565fc7.jpg, createdBy=f6da5502104, createdName=大郎该吃药了, createdTime=Sat Nov 27 06:33:31 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-27 大郎该吃药了

    药物的研发还是需要时间,静静等待就好了

    0

相关资讯

2021年11月26日简报:上海新增3例感染者,将以影响最小的方式完成此次疫情防控,无需担心和焦虑;南非发现新冠病毒新毒株B.1.1529,存在大量突变

截至北京时间2021年11月26日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6023万例,新增540,746例,达到260,238,

2021年11月22日简报:科学研究表明戴口罩和洗手是预防新冠病毒感染更有效的方式;法国再现新冠变种B.1.X或B.1.640;新加坡要求拒打疫苗者自付新冠治疗费

截至北京时间2021年11月22日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5739万例,新增467,308例,达到257,393,

Clin Nutrition: 住院时的营养风险与新冠肺炎老年患者的住院时间延长有关

营养风险概念的 一个重要特征是“营养风险与临床结局(outcome)密切相关”。只有改善临床结 局才能使患者真正受益,即改善临床结局是临床营养支持的终点(endpoint)。

2021年11月24日简报:新冠病毒跨物种传播,引发持续变异,结果好坏尚难预测;欧洲区域累计新冠死亡病例明年3月或超220万例;新西兰宣布放弃清零政策,与病毒共存;

截至北京时间2021年11月24日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5895万例,新增513,391例,达到258,957,

2021年11月23日简报:中国研发的中和抗体能降低78%的住院和死亡率,有望年底上市;美前卫生局长警告称美新冠病例今冬或激增

截至北京时间2021年11月23日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5830万例,新增412,810例,达到258,304,